1. CCLHD Research Repositories
  2. Research Hub
  3. Health Service Research
Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1414
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVerma, Abhishek K-
dc.date.accessioned2019-05-27T02:06:35Zen
dc.date.available2019-05-27T02:06:35Zen
dc.date.issued2009-11-
dc.identifier.citationVolume 79, Issue 11, pp. 773 - 774en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1414en
dc.description.abstractThis article discusses two new agents, Dabigatran and Rivaroxaban and their use in orthopaedic thromboprophylaxis. Their safety, efficacy and cost effectiveness is also discussed.en
dc.description.sponsorshipHaematologyen
dc.subjectDrug Therapyen
dc.titleNew agents for orthopaedic thromboprophylaxis: caution essential, but time will tellen
dc.typeJournal Articleen
dc.identifier.doi10.1111/j.1445-2197.2009.05099.xen
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/20078521en
dc.identifier.journaltitleANZ Journal of Surgeryen
dc.originaltypeTexten
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
Appears in Collections:Health Service Research
Show simple item record

Page view(s)

30
checked on Nov 26, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.